Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Clinical investigation is aimed to assess the performance and safety of web-based ARVO 2.0, for evaluating possible Attention-Deficit/Hyperactive Disorder (ADHD) symptoms in children. Possible ADHD symptoms are recorded by using specific predetermined neurocognitive performance indicators (NPI's), derived during/from the game.
Results of ARVO are compared to the Conners Continuous Performance Test 3rd Edition™ (CPT 3) that is a task-oriented, automated 14-minute computerized assessment of attention-deficit (AD) related problems in individuals aged 8 years and older.
Performance and safety of ARVO and CPT 3 are compared in two clinical investigation populations, 8-13 years old ADHD children and typically developing (TD) children of the same age. Test are performed by the subject while monitoring adult supervises safety of the use.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TD | Experimental | Children of 8-13 years of age without any neuropsychiatric diagnose (typically developed) |
|
| ADHD | Experimental | Children of 8-13 years of age with previously diagnosed ADHD symptoms |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ARVO 2.0 WEB | Device | Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached. The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed. |
| Measure | Description | Time Frame |
|---|---|---|
| ARVO and CPT 3 neuropsychiatric indicators (NPIs) | To confirm that ARVO is equivalent to (CPT 3) regarding predictive validity (AUC) | At Visit 1 test event (four weeks after V0 enrollment) |
| Children SSQ score | To confirm that ARVO is safe as defined by Simulator Sickness Score (SSQ) value 0, 1, or 2. | At Visit 1 (four weeks after V0 enrollment) immediately upon completed ARVO test |
| Measure | Description | Time Frame |
|---|---|---|
| ARVO and CPT 3 neuropsychiatric indicators (NPIs) | To confirm that ARVO is equivalent to CPT 3 regarding individual NPIs ability to differentiate ADHD and TD groups | Visit 1 test event (four weeks after V0 enrollment) |
| ARVO NPIs mean score and ADHR-RS for parent score |
Not provided
Inclusion Criteria:
ADHD group
The Inclusion criteria:
TD group
The Inclusion criteria:
Exclusion Criteria:
ADHD group
TD group
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sami Leppämäki, MD, PhD | Pro Neuron Oy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pro Neuron Oy | Espoo | 02650 | Finland |
By utilizing the data collected in this clinical investigation, the suitability of the web browser version of ARVO test to identify ADHD will be evaluated by metrics including number of correctly performed tasks, task efficiency, navigation efficiency, number of functions, and mouse movement speed. Additionally, it will be evaluated whether other metrics that are central to the assessment of ADHD can be identified from the collected data.
2024-2030
Scientific research as defined in the Clinical Investigation Plan and supporting documents.
Not provided
Not provided
Prospective, interventional, case control clinical investigation. Comparison of groups.
Equivalence study. Intervention model: cross-over assignment both groups are given both ARVO and Conners Continuous Performance Test 3rd Edition™ (CPT 3) tests.
Allocation: Propensity matching is used to ensure inter-group homogeneity in background variable with possible interaction effect to ARVO and CPT 3 score. Propensity matching: age and sex.
Not provided
Not provided
Not provided
Not provided
|
| Conners Continuous Performance Test 3rd Edition™ (CPT 3) | Other | Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter "X" appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed |
|
To confirm that ARVO is equivalent to ADHD-RS regarding concurrent validity (correlation) |
| Visit 1 test event (four weeks after V0 enrollment) |
| Smileyometer and Fun Sorter | To confirm that ARVO is superior to CPT 3 regarding use experience | Visit 1 test event (four weeks after V0 enrollment) |
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided